Google Secures Pentagon AI Deal for Classified Projects 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
The enormous rally in Kodak shares is expected to continue after its 318 percent increase on Wednesday on the strength of the Trump administration's announcement that will be transformed into a pharmaceutical producer and would receive a $765 million loan to launch Kodak Pharmaceuticals.
The news propelled the company's shares to a more than 200 percent jump in Tuesday trading that continued on Wednesday with the shares ending with a 318 percent increase.
The stocks climbed over 650 percent at its highest on Wednesday, prompting the New York Stock Exchange to halt trading 20 times.
Kodak, a pre-digital era giant producer of film and cameras, filed for bankruptcy in 2012 and pivoted to turn itself into a materials and chemical company.
It emerged as a restructured business in 2013.
Kodak Pharmaceuticals will produce generic active pharmaceutical ingredients to reduce America's dependency on foreign drug makers.
Kodak CEO Jim Continenza noted that since the company already manufactures essential materials for some pharmaceuticals, the new mission is only expanding that capacity.
He added that it would take around three to three and a half years to establish the new production capacity.
